The influenza vaccines market size has grown strongly in recent years. It will grow from $6.91 billion in 2023 to $7.44 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth observed in the historical period can be attributed to factors such as pandemic preparedness, public health initiatives, studies on vaccine effectiveness, recommendations from healthcare professionals, and global influenza surveillance efforts.
The influenza vaccines market size is expected to see strong growth in the next few years. It will grow to $10.1 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated growth in the forecast period can be attributed to factors such as climate and environmental considerations, improvements in healthcare accessibility, the emergence of new influenza strains, innovations in adjuvants and delivery systems, and the overall increase in healthcare expenditure. Major trends expected in the forecast period include the wider use of mRNA vaccine technology, a focus on pediatric immunization, implementation of seasonal influenza control measures, enhanced vaccination coverage in developing nations, and the adoption of tailored vaccination strategies.
The influenza vaccine market is anticipated to witness growth due to the increasing occurrences of seasonal influenza. Seasonal influenza, a respiratory illness caused by influenza viruses, tends to circulate and cause infections during specific periods, typically in colder months. This trend is influenced by factors such as antigenic drift, population susceptibility, environmental conditions, incomplete vaccine coverage, and the absence of universal vaccination. Influenza vaccines play a crucial role in reducing the incidence of seasonal influenza by providing immunization against circulating virus strains. For instance, as per the Central Drugs Standard Control Organization's October 2022 report, the estimated burden of influenza for 2021-2022 included nine million flu illnesses, 100,000 flu-related hospitalizations, 4 million flu-related medical visits, and 5,000 flu deaths. Hence, the increasing occurrences of seasonal influenza are steering the growth of the influenza vaccines market.
The growth of the influenza vaccines market is further expected to be propelled by the increasing aging population. This demographic trend refers to a rising proportion of elderly individuals within a society, and this population segment utilizes influenza vaccines to mitigate the heightened susceptibility to severe complications and mortality associated with influenza infections. The aging process may lead to a weakening immune system, rendering individuals more vulnerable to infectious diseases such as influenza. According to the World Health Organization (WHO) in October 2022, the global population of people aged 60 years and older is projected to double by 2050, reaching 2.1 billion. Therefore, the expanding aging population is a significant driver of the influenza vaccines market.
An emerging trend in the influenza vaccine market is the adoption of technologically advanced vaccine production methods. Companies operating in this market are embracing innovative vaccine production technologies to maintain their competitive positions. For example, in January 2023, GlaxoSmithKline PLC introduced the Multiple Antigen Presenting System (MAPS) for vaccine development, offering an innovative approach to developing effective vaccines against bacteria and viruses. This technology is particularly useful for rapid vaccine development in response to epidemic or pandemic outbreaks.
Major companies in the influenza vaccine market are focusing on advanced product innovations, such as quadrivalent seasonal influenza vaccines, to enhance their respiratory vaccine portfolios and financial standings. A quadrivalent seasonal influenza vaccine is designed to provide protection against four different flu viruses, including two influenza A viruses and two influenza B viruses. In September 2023, Clover Biopharmaceuticals Ltd. launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The quadrivalent composition enhances the vaccine's effectiveness across different influenza B strains compared to trivalent options.
In November 2022, Pfizer Inc. entered into a partnership with BioNTech SE to develop an mRNA combination vaccine for influenza and COVID-19. This collaboration aims to initiate a phase I trial for a single-dose mRNA-based combination addressing both respiratory diseases. BioNTech SE, a Germany-based immunotherapy developer, is partnering with Pfizer Inc., a US-based pharmaceutical and biotechnology company, to advance this innovative approach to respiratory disease prevention.
Major companies operating in the influenza vaccines market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Serum Institute of India Private Limited, Takeda Pharmaceutical Company Limited, Moderna Inc., Viatris Inc., CSL Limited, Seqirus Inc., Daiichi Sankyo Company Limited, China National Pharmaceutical Group Corporation, Shanghai Fosun Pharmaceutical Group Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., Novavax AB, Sinovac Biotech Co. Ltd., Green Cross Corporation, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Hualan Biological Engineering Inc., Valneva SE, Bharat Biotech International Limited, Vaxess Technologies Inc., Osivax, Gamma Vaccines Pty. Ltd.
North America was the largest region in the influenza vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the influenza vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of influenza vaccines are inactivated and live attenuated vaccines. Inactivated vaccines contain killed or inactivated microorganisms or viruses, stimulating an immune response without causing the disease. They are used to prevent infection and reduce the severity of illness caused by influenza viruses. Inactivated vaccines are available in both quadrivalent and trivalent formulations and are administered through injections and nasal sprays. These vaccines are suitable for both pediatric and adult populations and are distributed through various channels, including hospitals and pharmacies, government and institutional supply, and other distribution networks.
The influenza vaccines market research report is one of a series of new reports that provides influenza vaccines market statistics, including influenza vaccines industry global market size, regional shares, competitors with an influenza vaccines market share, detailed influenza vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the influenza vaccines industry. This influenza vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The influenza vaccines market consists of sales of recombinant influenza vaccines, high-dose influenza vaccines, cell-based influenza vaccines, and egg-based influenza vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The influenza vaccines market size is expected to see strong growth in the next few years. It will grow to $10.1 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated growth in the forecast period can be attributed to factors such as climate and environmental considerations, improvements in healthcare accessibility, the emergence of new influenza strains, innovations in adjuvants and delivery systems, and the overall increase in healthcare expenditure. Major trends expected in the forecast period include the wider use of mRNA vaccine technology, a focus on pediatric immunization, implementation of seasonal influenza control measures, enhanced vaccination coverage in developing nations, and the adoption of tailored vaccination strategies.
The influenza vaccine market is anticipated to witness growth due to the increasing occurrences of seasonal influenza. Seasonal influenza, a respiratory illness caused by influenza viruses, tends to circulate and cause infections during specific periods, typically in colder months. This trend is influenced by factors such as antigenic drift, population susceptibility, environmental conditions, incomplete vaccine coverage, and the absence of universal vaccination. Influenza vaccines play a crucial role in reducing the incidence of seasonal influenza by providing immunization against circulating virus strains. For instance, as per the Central Drugs Standard Control Organization's October 2022 report, the estimated burden of influenza for 2021-2022 included nine million flu illnesses, 100,000 flu-related hospitalizations, 4 million flu-related medical visits, and 5,000 flu deaths. Hence, the increasing occurrences of seasonal influenza are steering the growth of the influenza vaccines market.
The growth of the influenza vaccines market is further expected to be propelled by the increasing aging population. This demographic trend refers to a rising proportion of elderly individuals within a society, and this population segment utilizes influenza vaccines to mitigate the heightened susceptibility to severe complications and mortality associated with influenza infections. The aging process may lead to a weakening immune system, rendering individuals more vulnerable to infectious diseases such as influenza. According to the World Health Organization (WHO) in October 2022, the global population of people aged 60 years and older is projected to double by 2050, reaching 2.1 billion. Therefore, the expanding aging population is a significant driver of the influenza vaccines market.
An emerging trend in the influenza vaccine market is the adoption of technologically advanced vaccine production methods. Companies operating in this market are embracing innovative vaccine production technologies to maintain their competitive positions. For example, in January 2023, GlaxoSmithKline PLC introduced the Multiple Antigen Presenting System (MAPS) for vaccine development, offering an innovative approach to developing effective vaccines against bacteria and viruses. This technology is particularly useful for rapid vaccine development in response to epidemic or pandemic outbreaks.
Major companies in the influenza vaccine market are focusing on advanced product innovations, such as quadrivalent seasonal influenza vaccines, to enhance their respiratory vaccine portfolios and financial standings. A quadrivalent seasonal influenza vaccine is designed to provide protection against four different flu viruses, including two influenza A viruses and two influenza B viruses. In September 2023, Clover Biopharmaceuticals Ltd. launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The quadrivalent composition enhances the vaccine's effectiveness across different influenza B strains compared to trivalent options.
In November 2022, Pfizer Inc. entered into a partnership with BioNTech SE to develop an mRNA combination vaccine for influenza and COVID-19. This collaboration aims to initiate a phase I trial for a single-dose mRNA-based combination addressing both respiratory diseases. BioNTech SE, a Germany-based immunotherapy developer, is partnering with Pfizer Inc., a US-based pharmaceutical and biotechnology company, to advance this innovative approach to respiratory disease prevention.
Major companies operating in the influenza vaccines market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Serum Institute of India Private Limited, Takeda Pharmaceutical Company Limited, Moderna Inc., Viatris Inc., CSL Limited, Seqirus Inc., Daiichi Sankyo Company Limited, China National Pharmaceutical Group Corporation, Shanghai Fosun Pharmaceutical Group Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., Novavax AB, Sinovac Biotech Co. Ltd., Green Cross Corporation, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Hualan Biological Engineering Inc., Valneva SE, Bharat Biotech International Limited, Vaxess Technologies Inc., Osivax, Gamma Vaccines Pty. Ltd.
North America was the largest region in the influenza vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the influenza vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of influenza vaccines are inactivated and live attenuated vaccines. Inactivated vaccines contain killed or inactivated microorganisms or viruses, stimulating an immune response without causing the disease. They are used to prevent infection and reduce the severity of illness caused by influenza viruses. Inactivated vaccines are available in both quadrivalent and trivalent formulations and are administered through injections and nasal sprays. These vaccines are suitable for both pediatric and adult populations and are distributed through various channels, including hospitals and pharmacies, government and institutional supply, and other distribution networks.
The influenza vaccines market research report is one of a series of new reports that provides influenza vaccines market statistics, including influenza vaccines industry global market size, regional shares, competitors with an influenza vaccines market share, detailed influenza vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the influenza vaccines industry. This influenza vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The influenza vaccines market consists of sales of recombinant influenza vaccines, high-dose influenza vaccines, cell-based influenza vaccines, and egg-based influenza vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Influenza Vaccines Market Characteristics3. Influenza Vaccines Market Trends and Strategies32. Global Influenza Vaccines Market Competitive Benchmarking33. Global Influenza Vaccines Market Competitive Dashboard34. Key Mergers and Acquisitions in the Influenza Vaccines Market
4. Influenza Vaccines Market - Macro Economic Scenario
5. Global Influenza Vaccines Market Size and Growth
6. Influenza Vaccines Market Segmentation
7. Influenza Vaccines Market Regional and Country Analysis
8. Asia-Pacific Influenza Vaccines Market
9. China Influenza Vaccines Market
10. India Influenza Vaccines Market
11. Japan Influenza Vaccines Market
12. Australia Influenza Vaccines Market
13. Indonesia Influenza Vaccines Market
14. South Korea Influenza Vaccines Market
15. Western Europe Influenza Vaccines Market
16. UK Influenza Vaccines Market
17. Germany Influenza Vaccines Market
18. France Influenza Vaccines Market
19. Italy Influenza Vaccines Market
20. Spain Influenza Vaccines Market
21. Eastern Europe Influenza Vaccines Market
22. Russia Influenza Vaccines Market
23. North America Influenza Vaccines Market
24. USA Influenza Vaccines Market
25. Canada Influenza Vaccines Market
26. South America Influenza Vaccines Market
27. Brazil Influenza Vaccines Market
28. Middle East Influenza Vaccines Market
29. Africa Influenza Vaccines Market
30. Influenza Vaccines Market Competitive Landscape and Company Profiles
31. Influenza Vaccines Market Other Major and Innovative Companies
35. Influenza Vaccines Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Influenza Vaccines Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on influenza vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for influenza vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Vaccine Type: Inactivated; Live Attenuated
2) By Valency: Quadrivalent; Trivalent
3) By Route Of Administration: Injection; Nasal Spray
4) By Age Group: Pediatric; Adult
5) By Distribution Channel: Hospitals and Pharmacies; Government and Institutional Supply; Other Distribution Channels
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Sanofi-Aventis LLC.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi-Aventis LLC.
- AstraZeneca PLC
- GlaxoSmithKline plc.
- Serum Institute of India Private Limited
- Takeda Pharmaceutical Company Limited
- Moderna Inc.
- Viatris Inc.
- CSL Limited
- Seqirus Inc.
- Daiichi Sankyo Company Limited
- China National Pharmaceutical Group Corporation
- Shanghai Fosun Pharmaceutical Group Co. Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Shionogi & Co. Ltd.
- Liaoning Cheng Da Biotechnology Co. Ltd.
- Novavax AB
- Sinovac Biotech Co. Ltd.
- Green Cross Corporation
- Emergent BioSolutions Inc.
- Walvax Biotechnology Co. Ltd.
- Hualan Biological Engineering Inc.
- Valneva SE
- Bharat Biotech International Limited
- Vaxess Technologies Inc.
- Osivax
- Gamma Vaccines Pty. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 7.44 Billion |
| Forecasted Market Value ( USD | $ 10.1 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
